Eric Legangneux

707 total citations
29 papers, 581 citations indexed

About

Eric Legangneux is a scholar working on Molecular Biology, Plant Science and Cognitive Neuroscience. According to data from OpenAlex, Eric Legangneux has authored 29 papers receiving a total of 581 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Plant Science and 5 papers in Cognitive Neuroscience. Recurrent topics in Eric Legangneux's work include Sphingolipid Metabolism and Signaling (7 papers), Sleep and related disorders (5 papers) and Sleep and Wakefulness Research (5 papers). Eric Legangneux is often cited by papers focused on Sphingolipid Metabolism and Signaling (7 papers), Sleep and related disorders (5 papers) and Sleep and Wakefulness Research (5 papers). Eric Legangneux collaborates with scholars based in Switzerland, United States and India. Eric Legangneux's co-authors include Anne Gardin, Donald R. Johns, Kasra Shakeri‐Nejad, C. Gomeni, Michel Herrou, Odile Spreux‐Varoquaux, Zhenzhong Su, Jean Dawson, Neil Stanley and Ian Hindmarch and has published in prestigious journals such as Neurology, Journal of Affective Disorders and Clinical Pharmacokinetics.

In The Last Decade

Eric Legangneux

29 papers receiving 555 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Legangneux Switzerland 14 179 163 123 118 91 29 581
Fernando Brivio Italy 17 106 0.6× 96 0.6× 136 1.1× 60 0.5× 31 0.3× 34 702
Rika Aizawa Japan 11 88 0.5× 237 1.5× 32 0.3× 200 1.7× 33 0.4× 13 569
Sunanda Tuladhar India 10 162 0.9× 87 0.5× 32 0.3× 71 0.6× 15 0.2× 17 555
Christian von Hehn United States 10 98 0.5× 44 0.3× 62 0.5× 32 0.3× 114 1.3× 21 509
Jill Goddard United States 10 134 0.7× 55 0.3× 59 0.5× 74 0.6× 24 0.3× 11 574
Yixuan Niu China 10 113 0.6× 209 1.3× 136 1.1× 28 0.2× 14 0.2× 18 555
Kelly R. Jacobs Australia 13 276 1.5× 22 0.1× 233 1.9× 37 0.3× 64 0.7× 16 921
Bart Laurijssens United States 10 84 0.5× 57 0.3× 143 1.2× 16 0.1× 59 0.6× 15 560
Soo Jin Kwon South Korea 11 185 1.0× 137 0.8× 36 0.3× 110 0.9× 23 0.3× 18 597
Kamal Albarazanji United States 13 210 1.2× 131 0.8× 73 0.6× 76 0.6× 10 0.1× 22 734

Countries citing papers authored by Eric Legangneux

Since Specialization
Citations

This map shows the geographic impact of Eric Legangneux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Legangneux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Legangneux more than expected).

Fields of papers citing papers by Eric Legangneux

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Legangneux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Legangneux. The network helps show where Eric Legangneux may publish in the future.

Co-authorship network of co-authors of Eric Legangneux

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Legangneux. A scholar is included among the top collaborators of Eric Legangneux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Legangneux. Eric Legangneux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shakeri‐Nejad, Kasra, et al.. (2020). Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects. Clinical Therapeutics. 42(1). 175–195. 8 indexed citations
2.
3.
Gardin, Anne, Mike Ufer, Eric Legangneux, et al.. (2018). Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects. Clinical Pharmacokinetics. 58(3). 349–361. 23 indexed citations
4.
Gardin, Anne, et al.. (2018). Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. European Journal of Clinical Pharmacology. 74(12). 1593–1604. 11 indexed citations
5.
Gardin, Anne, et al.. (2018). Absolute Bioavailability of Single, Oral Dose of Siponimod in Healthy Subjects (P3.402). Neurology. 90(15_supplement). 1 indexed citations
6.
Ufer, Mike, Alexandros Sagkriotis, Ganesan Subramanian, et al.. (2016). Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056). Clinical Therapeutics. 38(12). 2589–2597. 2 indexed citations
7.
Legangneux, Eric, Kasra Shakeri‐Nejad, Vassilios Aslanis, et al.. (2016). Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects. Clinical Therapeutics. 38(3). 631–645.e1. 8 indexed citations
8.
9.
Shakeri‐Nejad, Kasra, Vassilios Aslanis, Louise Mooney, et al.. (2015). Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects. Clinical Therapeutics. 37(11). 2489–2505.e2. 13 indexed citations
10.
Chakraborty, Abhijit, Marie‐Laure Rouzade‐Dominguez, Annamária Jakab, et al.. (2015). Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women. International Journal of Clinical Pharmacology and Therapeutics. 53(7). 550–556. 1 indexed citations
11.
Hoyer, Daniël, Markus Fendt, Laura H. Jacobson, et al.. (2013). Distinct effects of IPSU and suvorexant on mouse sleep architecture. Frontiers in Neuroscience. 7. 235–235. 35 indexed citations
12.
Legangneux, Eric, Anne Gardin, & Donald R. Johns. (2012). Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. British Journal of Clinical Pharmacology. 75(3). 831–841. 56 indexed citations
13.
Hindmarch, Ian, et al.. (2006). A double‐blind, placebo‐controlled investigation of the residual psychomotor and cognitive effects of zolpidem‐MR in healthy elderly volunteers. British Journal of Clinical Pharmacology. 62(5). 538–545. 41 indexed citations
14.
Greenblatt, David J., Eric Legangneux, Jerold S. Harmatz, et al.. (2006). Dynamics and Kinetics of a Modified‐Release Formulation of Zolpidem: Comparison With Immediate‐Release Standard Zolpidem and Placebo. The Journal of Clinical Pharmacology. 46(12). 1469–1480. 42 indexed citations
15.
Blin, Olivier, Joëlle Micallef, Christine Audebert, & Eric Legangneux. (2006). A Double-blind, Placebo- and Flurazepam-controlled Investigation of the Residual Psychomotor and Cognitive Effects of Modified Release Zolpidem in Young Healthy Volunteers. Journal of Clinical Psychopharmacology. 26(3). 284–289. 27 indexed citations
16.
Legangneux, Eric, et al.. (2003). Lack of effect of amisulpride on the pharmacokinetics and safety of lithium. The International Journal of Neuropsychopharmacology. 6(2). 103–109. 9 indexed citations
17.
18.
Legangneux, Eric, John McEwen, Keith Wesnes, et al.. (2000). The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. Journal of Psychopharmacology. 14(2). 164–171. 36 indexed citations
19.
Appel‐Dingemanse, Silke, et al.. (1999). Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5‐HT4 receptor agonist, following oral and intravenous administration. British Journal of Clinical Pharmacology. 47(5). 483–491. 36 indexed citations
20.
Rosenzweig, P., Alain Patat, O. Curet, et al.. (1998). Clinical pharmacology of befloxatone: a brief review. Journal of Affective Disorders. 51(3). 305–312. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fernando Brivio Breakdown of academic impact, for papers by Rika Aizawa Breakdown of academic impact, for papers by Sunanda Tuladhar Breakdown of academic impact, for papers by Christian von Hehn Breakdown of academic impact, for papers by Jill Goddard Breakdown of academic impact, for papers by Yixuan Niu Breakdown of academic impact, for papers by Kelly R. Jacobs Breakdown of academic impact, for papers by Bart Laurijssens Breakdown of academic impact, for papers by Soo Jin Kwon Breakdown of academic impact, for papers by Kamal Albarazanji
Rankless by CCL
2026